Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis- and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment

Molecular Brain Research

Volumn 54, Issue 1, 1998, Pages 92-100

  Chih Hui Chen, Andrew ^a   McDonald, Bernard ^b   Moss, Stephen J ^b   Gurling, Hugh M D ^a  

^a Windeyer Institute of Medical Sciences   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic drugs; Flupenthixol; Gene expression; mRNA; Multiprobe oligonucleotide solution hybridization (MOSH); N methyl D aspartate (NMDA); Schizophrenia

Indexed keywords

BRAIN RECEPTOR; FLUPENTIXOL; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; RECEPTOR SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CEREBELLUM; CIS ISOMER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FRONTAL CORTEX; GENE EXPRESSION REGULATION; HYBRIDIZATION; IMMUNOBLOTTING; IMMUNOREACTIVITY; ISOMER; MALE; MULTIPROBE OLIGONUCLEOTIDE SOLUTION HYBRIDIZATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARIETAL LOBE; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; TRANS ISOMER;

ADMINISTRATION, ORAL; ANIMALS; FLUPENTHIXOL; GENE EXPRESSION REGULATION; MALE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SCHIZOPHRENIA;

ANIMALIA; EUKARYOTA;

EID: 0344624856     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(97)00326-4     Document Type: Article

References (43)

1. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E. Jr., Jones E.G. Selective alterations in gene expression for NMDA receptor subunit in prefrontal cortex of schizophrenics. J. Neurosci. 16:1996;19-30.
2. Allen R.M., Young S.J. Phecyclidine-induced psychosis. Am. J. Psychiatry. 135:1978;1081-1084.
3. D.S. Bell, Comparison of amphetamine psychosis and schizophrenia, Br. J. Psychiatry (1965) 701-707.
4. Benes F.M. Altered glutamatergic and GABAergic mechanisms in the cingulate cortex of the schizophrenic brain. Arch. Gen. Psychiatry. 52:1995;1015-1018.
5. Bradford M.M. A refined and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248.
6. Breese C.R., Freedman R., Leonard S.S. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674:1995;82-90.
7. Buckland P.R., O'Donovan M.C., McGuffin P. Changes in dopamine D1, D2, D3 receptor mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology. 106:1992;479-483.
8. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
9. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and protein from cell and tissue samples. BioTechniques. 15:1993;532-536.
10. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry. 3:1996;241-253.
11. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
12. De La Concha A., McKie J., Hodgkinson S., Mankoo B.S., Gurling H.M.D. Stereospecific effect of flupenthixol on neuroreceptor gene expression. Mol. Brain. Res. 10:1991;123-127.
13. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52:1989;1781-1786.
14. Deakin J.F. Neuropsychological implications of brain changes in schizophrenia: an overview. Psychopathology. 27:1994;251-254.
15. Eastwood S.L., McDonald B., Burnet P.W.J., Beckwith J.P., Kerwin R.W., Harrison P.J. Decreased expression of mRNA encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain. Res. 29:1995;211-223.
16. Enna S.J., Bennett J.P. Jr., Burt D.R., Creese I., Snyder S.H. Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature. 263:1976;338-341.
17. Faedda G., Kula N.S., Baldessarini R.J. Pharmacology of binding of 3H-SCH-23390 to D-1 dopaminergic receptor sites in rat striatal tissue. Biochem. Pharmacol. 3:1989;473-480.
18. Fitzgerald L.W., Deutch A.Y., Gasic G., Heinemann S.F., Nestler E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15:1995;2453-2461.
19. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
20. S.E. Hyman, E.J. Nestler, The Molecular Foundations of Psychiatry, Washington, DC, American Psychiatric Press, 1993, pp. 141-150.
21. Hyman S.E., Nestler E.J. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am. J. Psychiatry. 153:1996;151-162.
22. Ishii T., Moriyoshi K., Sugihara H., Sakurada K., Kadotani H., Yokoi M.J., Akazawa C., Shigemoto R., Mizuno N., Nakinishi S. Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits. J. Biol. Chem. 268:1993;2836-2843.
23. Ishimaru M., Kurumaji A., Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry. 35:1994;84-95.
24. Javitt D.C., Zukin S.R. Recent advances in phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
25. E.C. Johnstone, T.J. Crow, C.D. Frith, M.W.P. Carney, J.S. Price, Mechanism of the antipsychotic effect in the treatment of acute schizophrenia, Lancet, i (1978) 848-851.
26. Jones S.M., Snell L.D., Johnson K.M. Characterization of the binding of radioligands to the N-methyl-D-aspartate, phencyclidine, and glycine receptors in buffy coat membranes. J. Pharmacol. Methods. 21:1989;161-168.
27. Karreman M., Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J. Neurochem. 66:1996;589-598.
28. Kerwin R.W. Glutamate receptor, microtubule associated proteins and developmental anomaly in schizophrenia: an hypothesis. Psychol. Med. 23:1993;547-551.
29. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
30. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology. 124:1996;2-34.
31. Krebs M.O., Desce J.M., Kemel M.L., Gauchy C., Godeheu G., Cheramy A., Glowinski J. Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic NMDA receptors on dopaminergic nerve terminals. J. Neurochem. 56:1991;81-85.
32. Luby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. Model psychoses and schizophrenia. Am. J. Psychiatry. 119:1962;61-67.
33. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17:1991;263-287.
34. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 256:1992;1217-1221.
35. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 12:1994;529-540.
36. Moriyoshi K., Masu M., Ishii T., Shigemoto R., Mizuno N., Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 354:1991;31-37.
37. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
38. Oretti R.G., Spurlock G., Buckland P.R., McGuffin P. Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains. Neurosci. Lett. 177:1994;39-43.
39. Peroutka S.J., Snyder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry. 137:1980;1518-1522.
40. See R.E., Ellison G. Comparison of chronic administration of haloperidol and atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Eur. J. Pharmacol. 181:1990;175-186.
41. P. Seeman, Dopamine receptors in human disease, in: I. Creese, C.M. Fraser (Eds.), Dopamine Receptors, Receptor Biochemistry and Methodology, Vol. 8, Liss, New York, (1987) pp. 233-245.
42. Tarazi F.I., Florijn W.J., Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology. 128:1996;371-379.
43. Youngren K.D., Daly D.A., Moghaddam B. Distinct actions of endogenous excitatory amino acids on the outflow of dopamine in the nucleus accumbens. J. Pharmacol. Exp. Ther. 264:1993;289-293.